Oncology

Top Story

Atezolizumab-bevacizumab combination delays quality-of-life deterioration in hepatocellular carcinoma

Atezolizumab-bevacizumab combination delays quality-of-life deterioration in hepatocellular carcinoma
January 22, 2020
FDA News

FDA grants orphan drug designation to durvalumab-tremelimumab combination for liver cancer

January 21, 2020
The FDA granted orphan drug designation to durvalumab and tremelimumab for treatment of patients with advanced hepatocellular carcinoma. Durvalumab (Imfinzi…

Combination therapy trial for locally advanced, metastatic HCC underway

January 16, 2020
CStone Pharmaceuticals and Blueprint Medicines Corporation announced the first patient dosed in a phase 1b/2 trial of fisobatinib in combination with CS1001 for the…
In the Journals

Modified PAGE-B score classifies HCC risk in patients undergoing HBV therapy

January 15, 2020
The PAGE-B score and a modified PAGE-B score identified which patients on antiviral therapy for chronic hepatitis B had a low risk for hepatocellular carcinoma…
More Headlines »